SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is seeing heightened community engagement as investors debate the impact of upcoming earnings and potential M&A activity amidst ongoing discussions about short interest and market manipulation. Traders are closely monitoring technical setups and institutional positioning, with many retail participants expressing both long-term conviction and frustration over current price volatility.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a viral meme coin on the Solana blockchain, driven by aggressive community promotion and high-volatility price swings. Investors are actively debating its potential for massive percentage gains versus its high-risk profile as a speculative pump-and-dump asset.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as investors weigh its aggressive AI infrastructure spending against broader geopolitical uncertainty and cooling ad revenue sentiment. The community remains deeply divided, with many debating the impact of increased competition from OpenAI and Anthropic versus the long-term value potential of its cloud and quantum computing initiatives.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is currently a focal point for retail investors, with intense community debate over whether recent downward price action reflects a deeper fundamental disconnect or an opportunity to accumulate shares at discounted levels. Investors are closely monitoring its performance as a proxy for crypto and market sentiment, while navigating heightened uncertainty surrounding regulatory scrutiny on prediction markets and broader geopolitical pressures.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubo is experiencing intense downward pressure and volatility as shareholders react to the announcement of a 1-for-12 reverse stock split, sparking heated debates over the company's long-term viability and management's effectiveness. While some retail investors are betting on a potential institutional shift and short squeeze due to the reduced float, many are voicing frustration over lost value, lack of clear guidance, and declining content offerings.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility and downward pressure as investors weigh a new private-label energy drink launch from Costco against the company's long-term growth and international expansion. While some in the community express frustration over the stock's recent performance and management's lack of communication, others argue the sell-off is an overreaction driven by algorithmic trading and short-term panic rather than a fundamental shift in the company's market position.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is experiencing significant market volatility and high trading volume as investors debate the impact of a recent short-seller report alleging channel stuffing, a claim the company's long-term supporters aggressively refute by pointing to strong fundamental growth and institutional buying. While some retail traders are expressing frustration over the recent price decline and lack of immediate management commentary, many are interpreting the current dip as a potential entry point based on the firm's ongoing share repurchase program and long-term outlook.

Alphabet Inc - Ordinary Shares - Class C

Alphabet Inc. (GOOG/GOOGL) is trending following reports of a multi-billion dollar AI chip rental deal with Meta, signaling a potential shift in how big tech giants utilize hardware resources. Community sentiment is mixed, with active discussions focused on whether this partnership poses a direct challenge to Nvidia's dominance in the AI infrastructure space and how the market will respond to Alphabet's pivot toward selling its proprietary TPU technology.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and retail interest as investors speculate on its concentrated exposure to high-profile private AI and defense companies like OpenAI, Anthropic, and SpaceX. While some community members are betting on continued momentum due to the limited float and lockup periods for early investors, others are warning that the current market price represents a substantial premium over the fund's intrinsic net asset value.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is trending following an analyst upgrade from Susquehanna and positive sentiment surrounding its role as a key supplier for Nvidia's new data center chips. The community is actively debating the company's valuation versus its long-term potential in AI infrastructure, with many traders looking for a breakout from current technical support levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Energous Corporation (WATT) fell 5% on Tuesday after Fugazi Research termed it a business funded by dilution. &nbsp;“After more than a decade, WATT has not built a business that funds itself—it has built one that funds itself through shareholders,” Fugazi said while adding that continued dilution is not a risk but the model with the company.As per the firm, Energous is “uninvestable and will likely turn shareholders into bagholders, with shares likely to revisit single-digit pricing.”Get updates to this developing story directly on Stocktwits.

In this photo illustration, the Energous Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Are WATT Shares Down Today?

As per Fugazi Research, Energous is “uninvestable and will likely turn shareholders into bagholders, with shares likely to revisit single-digit pricing.”

Equity

As per Fugazi Research, Energous is “uninvestable and will likely turn shareholders into bagholders, with shares likely to revisit single-digit pricing.”


<ul class="summary-bullets"><li>The company stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.</li><li>Last week, Outlook Therapeutics announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.</li><li>In December 2025, the FDA issued a Complete Response Letter for ONS-5010 / LYTENAVA, saying it could not approve the treatment in its current form for wet AMD.</li></ul>Outlook Therapeutics Inc. (OTLK) shares plunged 32% in Tuesday’s pre-market trade after the company announced a proposed public offering of its common stock and accompanying warrants.Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25. The company said it expects aggregate gross proceeds of $5 million and that the offering is expected to close on Wednesday, March 25, 2026.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/OTLK">Outlook Therapeutics</a> trended in the ‘extremely bearish’ territory, with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">Why Did Outlook Therapeutics Announce The Offering?</h2>Outlook Therapeutics stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.Last week, the company announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.Earlier this month, Outlook Therapeutics provided an update with respect to a meeting with the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Application for its treatment of wet age-related macular degeneration (wet AMD).In December 2025, the company said that the FDA issued a Complete Response Letter for its investigational treatment, ONS-5010 / LYTENAVA (bevacizumab-vikg), stating that it cannot approve the application in its present form for the treatment of wet AMD.The company said that if the FDA approves it, bevacizumab-vikg has the potential to be the first ophthalmic formulation of bevacizumab-vikg approved by the regulator for use in ophthalmology.Bevacizumab-vikg is a lab-made antibody that targets a protein called VEGF, which helps blood vessels grow. By blocking VEGF from binding to its receptors on blood vessel cells, the drug prevents the formation of new blood vessels.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Outlook Therapeutics’ proposed offering was&nbsp;criticized&nbsp;by a user on the platform, who called out the company for not giving a roadmap on how it intends to use the money, other than meeting its working capital and general corporate needs.<stembedurl>https://stocktwits.com/HarveySpecter20/message/648356634</stembedurl>Another user highlighted the lack of data on the uptake of the investigational treatment from patients.<stembedurl>https://stocktwits.com/updownsides/message/648355300</stembedurl><a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> is down 80% year-to-date and 79% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 16% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 38%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fidelity-backs-elon-musk-tesla-spacex-terafab-project-datacenters-in-space/cZ3mK7PRI0u">Elon Musk's Joint Tesla, SpaceX Terafab Project Makes A 'Ton Of Sense', Says Investor Fidelity: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Is OTLK Stock Falling Today?

Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25.

<ul class="summary-bullets"><li>The company expects shipments to start in the second quarter, and be completed by the middle of the third quarter in 2026.</li><li>The company’s CFO, Stefan Murry, said that the reliable transceiver capacity is critical for the supply chain strategies of AAOI’s customers.&nbsp;</li><li>Murry added that the initial 800G volume order is likely to be the first of many more orders.</li></ul>Shares of Applied Optoelectronics Inc. (AAOI) jumped more than 4% in Monday’s extended trading hours after it announced that it received a new volume order from one of its hyperscale customers.The company, without naming the customer, said it had received an order for 800G single-mode data center transceivers, worth more than $53 million, intended to expand the customer’s network capacity for AI-driven workloads.After product qualifications, the company expects shipments to start in the second quarter, and be completed by the middle of the third quarter in 2026.<h2 class="st-heading-2">Leadership Take</h2>Founder, Chairman, and CEO of the company, Dr. Thompson Lin, noted the acceleration in AI infrastructure expansion, saying that it required significantly higher bandwidth at scale.“Our customers are adopting 800G not just for capacity and performance, but to manage long-term operating costs. Deploying 800G now helps to prevent network bottlenecks, improves power efficiency and lowers cost per bit, reducing the need for frequent upgrades,” Lin said.Meanwhile, the company’s CFO, Stefan Murry, said that the reliable transceiver capacity is critical for the supply chain strategies of AAOI’s customers."This early order for 800G is expected to support GPU cluster buildup, in line with our customer's large-scale infrastructure expansion plans,” Murry said.In addition, Murry said that the deal followed the prior week's announcement of 1.6Tb orders from this same customer, and that the initial 800G volume order, totaling more than $53 million, is likely to be the first of many more orders as the customer scales for rollouts across its clusters and regions.<h2 class="st-heading-2">AI Hardware</h2>Last week, Applied Optoelectronics showcased advanced data center solutions at the Optical Fiber Communications Conference, highlighting its transceiver lineup from 100G to 1.6T and a live 6.4T on-board optics demo.The company also showcased a 400mW continuous wave laser for 25dBm External Laser Small Form-Factor Pluggable (ELSFP), designed to support high-bandwidth AI systems. The solution will enable robust link budgets for CPO/NPO architectures while ensuring reliability and serviceability for mission-critical GPU clusters, the company said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AAOI">AAOI stock</a> was in the ‘bullish’ territory at the time of writing, amid ‘normal’ message volumes.Shares of the company have gained nearly 142% this year.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/meta-hires-ex-google-ex-stripe-dreamer-team-sans-tech-forsuperintelligence-push-report/cZ3mVk4RIKR">Meta Hires Ex-Google, Ex-Stripe Dreamer Team Sans Tech For Superintelligence Push: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Workers use microscopes in the production facility at Applied Optoelectronics Tuesday, May 10, 2016, in Houston.  (Photo by Karen Warren/Houston Chronicle via Getty Images)

Why Did AAOI Stock Jump After-Hours Today?

Applied Optoelectronics announced that it had received an order for 800G single-mode data center transceivers from one of its hyperscale customers. 

<ul class="summary-bullets"><li>YZi Labs criticized the company’s board for approving a roughly $2 million exit package for the outgoing CEO despite these control weaknesses.</li><li>It said that the CEO’s transition agreement includes payments and restrictions that may limit his ability to assist shareholders, prompting concerns about transparency and accountability.</li><li>It also pointed to filings that showed the BNB digital asset treasury paid millions in fees to an entity controlled by a sitting board member, raising potential conflicts of interest concerns.</li></ul>CEA Industries (BNC) shares continued to rise in afternoon trade on Monday while Changpeng ‘CZ’ Zhao-linked YZi Labs issued a statement “condemning” governance breakdowns at the company, including the nearly $2 million payout for outgoing CEO David Namdar.YZi Labs, which is a major shareholder in the firm, accused CEA Industries of serious mismanagement, including weak financial controls, questionable insider payments, and approving a nearly $2 million payout to its outgoing CEO under suspicious circumstances. In its note, the firm suggested CEA board actions may be part of a broader effort to maintain control during a shareholder dispute. It demanded transparency and accountability from the board.<a href="https://stocktwits.com/symbol/BNC/">BNC’s stock</a> was up 1.94% in afternoon trade, with retail sentiment on Stocktwits trending in ‘bullish’ territory over the past day. Chatter stayed at ‘normal’ levels.&nbsp;The company holds Binance Coin (BNB) as the primary digital asset in its treasury. According to the CEA Industries’ dashboard, the company currently holds 515,544 BNB worth around $328 million. It’s currently running a 25% loss, with the value of its holdings at $112 million in the red.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_23_140430_png_a910c0a033.webp" alt="Screenshot 2026-03-23 140430.png" width="1262" height="140"><figcaption>BNC retail sentiment and message volume on March 23 as of 1:05 p.m. ET | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/coins/binancecoin">BNB’s price</a> rose 1.3% in the last 24 hours to around $437 on Monday afternoon. Retail sentiment around the altcoin on Stocktwits remained in ‘bearish’ territory, while chatter rose to’ high’ from ‘normal’ levels over the past day.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_23_140444_png_249674f9b2.webp" alt="Screenshot 2026-03-23 140444.png" width="1258" height="141"><figcaption>BNB retail sentiment and message volume on March 23 as of 1:05 p.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Internal Control Failures Raise Red Flags</h2>YZi Labs accused the company’s board of failing to uphold basic standards of oversight, pointing to filings that show the chief executive previously held overlapping financial reporting responsibilities. It stated that such arrangements are widely viewed as a serious red flag in public markets.YZi Labs added that the filings disclosed a “material weakness” in internal controls, with insufficient processes to ensure the accuracy of key financial data across areas such as revenue, taxes, and stock-based compensation.&nbsp;While the company has since appointed a new chief financial officer, YZi Labs argued that the move alone does not resolve deeper structural issues.<h2 class="st-heading-2">$2 Million CEO Exit Package Draws Scrutiny</h2>At the center of the dispute is a transition agreement for outgoing CEO David Namdar, which YZi Labs estimated to be worth roughly $1.98 million. The package includes retroactive consulting fees, future monthly payments, and a substantial lump-sum payout tied to restrictive covenants.The firm raised concerns that provisions in the agreement could limit the former executive’s ability to assist shareholders or participate in potential legal actions. The firm suggested these terms may restrict transparency at a time when investors are seeking greater clarity around the company’s governance practices.<blockquote>“Public companies do not retroactively patch governance failures with $2 million golden parachutes and shadow equity plans.”&nbsp;– Alex Odagiu, Investment Partner, YZi Labs.</blockquote><h2 class="st-heading-2">CEA Industries’ Board Treats Company Like A ‘Piggy Bank’</h2>YZi Labs also criticized what it described as excessive related-party transactions, citing millions of dollars in fees paid to an asset management entity controlled by a sitting board member. It said that filings showed CEA Industries paid approximately $2 million to the entity in a single quarter.Moreover, CZ’s family office flagged inconsistencies in share count disclosures and questioned the timing of recent corporate actions. It suggested the actions seemed to coincide with an ongoing shareholder effort to influence company governance. “This Board continues to treat a Nasdaq-listed company like a private piggy bank,” stated Alex Odagiu, Investment Partner at YZi Labs.The firm is now calling on the board to justify the CEO’s exit package, address internal control deficiencies with a clear remediation plan, and provide greater transparency around related-party dealings and disclosure discrepancies.YZi Labs is widely described as Binance founder Zhao’s “family office” investment vehicle, created by spinning out the former Binance Labs venture arm into an independent firm that invests his capital across Web3, AI, and biotech.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/mstr-stock-rises-after-strategy-announces-44-billion-capital-raise-expansion/cZ3mWcDRI0N">MSTR Stock Rises After $44 Billion Capital Raise Plan Expansion</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representation of cryptocurrencies and Binance Coin logo displayed on a phone screen are seen in this illustration photo taken in Krakow, Poland on December 15, 2022. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

CEA Industries Board Treated Firm Like ‘Piggy Bank’, Says YZi Labs Condemning $2 Million CEO Exit

YZi Labs alleged “catastrophic” control failures at CEA Industries, insider payments, and a deal that may restrict shareholder transparency.

Cryptocurrency

<ul class="summary-bullets"><li>Mobileye stated that its in-cabin sensing platform includes both DMS and Occupant Monitoring, running alongside Advanced Driver Assistance System perception on a single chip.</li><li>The company stated that its DMS focuses on driver safety at a time when there is an increasing push for autonomous driving.</li><li>Mobileye added that its DMS is designed to correlate driver gaze with real-world road conditions from ADAS cameras, to catch distractions that cabin-only systems may miss.</li></ul>Tesla Inc.’s (TSLA) autonomous driving rival Mobileye Global Inc. (MBLY) on Monday announced that it has secured a deal with a leading U.S. automaker.Mobileye stated that the company will integrate the Mobileye Driver Monitoring System into future vehicles equipped with Mobileye's EyeQ6L system-on-chip, with the start of production targeted for 2027<a href="https://stocktwits.com/symbol/MBLY">Mobileye shares</a> soared more than 8% in Monday’s pre-market trade before paring some of the gains to hover 4% higher at the time of writing. Retail sentiment on Stocktwits around the company trended in the ‘neutral’ territory.Tesla had partnered with Mobileye to develop the Elon Musk-led EV giant’s Autopilot driving system. However, the partnership ended in 2016 when Mobileye partnered with German automaker BMW.<h2 class="st-heading-2">How Does Mobileye’s DMS Work?</h2>Mobileye stated that its in-cabin sensing platform includes both DMS and Occupant Monitoring (OMS), running alongside Advanced Driver Assistance System (ADAS) perception on a single chip.The platform combines in-cabin sensing with external road perception to assess driver engagement based on driving conditions, tracking where the driver is looking and whether their attention aligns with the road environment.“Automakers are looking to scale advanced driving features across their lineups without the cost penalty of additional hardware or complex system integration. Mobileye DMS delivers on both,” the company stated.<h2 class="st-heading-2">Focusing On Safety</h2>Mobileye stated that its DMS focuses on driver safety, at a time when there is an increasing push for autonomous driving. The company added that its DMS is designed to correlate driver gaze with real-world road conditions from ADAS cameras, to catch distractions that cabin-only systems may miss and recognize when the driver is already aware.This system results in fewer false alerts, more precise interventions, and a higher level of autonomy, the company added.<a href="https://stocktwits.com/symbol/MBLY">MBLY stock</a> is down 24% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/TSLA">TSLA stock</a> is down 16%. The Vanguard Extended Market Index Fund ETF (VXF) is up 14% over the past 12 months, while the Roundhill Robotaxi Autonomous Vehicles &amp; Technology ETF (CABZ) is down 18%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-postpone-military-strikes-iran-power-plants-5-days/cZ3mJhoRI0I">Dow Futures Soar 1,200 Points After Trump Postpones All Military Strikes Against Iranian Power Plants For 5 Days</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Mobileye Global Inc.

Tesla’s Autonomous Driving Rival Mobileye Secures Deal With Major US Automaker — MBLY Stock Gains

Mobileye stated that it will integrate its Driver Monitoring System into future vehicles equipped with the EyeQ6L system-on-chip.

Mobileye Secures Deal With Major US Automaker — MBLY Stock Gains

<ul class="summary-bullets"><li>The thinning liquidity, weak Q1 2026 guidance, and declining near-term forecasts, coupled with interim losses and the lack of catalysts, are key concerns for the firm, the analyst said.&nbsp;</li><li>On Thursday, FiscalNote reported $22.2 million in revenues for Q4 2025, below consensus estimates of $22.72 million.</li><li>The data and analytics company said that it plans to reduce about 25% of its workforce in the upcoming year to improve its cash position.</li></ul>Shares of FiscalNote Holdings (NOTE) plunged by over 16% on Friday amid fourth-quarter (Q4) 2025 earnings results on Thursday that disappointed Wall Street and retail investors.The data and analytics company, which received early seed money from American businessman Mark Cuban, posted revenue and earnings that missed analysts’ expectations amid subscription declines and higher operating expenses.Meanwhile, Roth Capital lowered the price target on FiscalNote to $3 from $5, and kept a ‘Buy’ rating on the shares after the lackluster results, according to TheFly.<h2 class="st-heading-2">Analyst Rationale</h2>Roth Capital noted FiscalNote's Q4 revenue miss, while highlighting that the company’s adjusted earnings before interest, taxes, depreciation, and amortization of $2.5 million exceeded its $2 million forecast.Despite a workforce reduction to improve profitability, the company’s free cash flow is not expected to improve until the first-quarter (Q1) of 2027.The thinning liquidity, weak Q1 2026 guidance, and declining near-term forecasts, coupled with interim losses and the lack of catalysts are key concerns for the firm, the analyst said.<h2 class="st-heading-2">Earnings Snapshot</h2>FiscalNote reported $22.2 million in revenues for Q4 2025, below consensus estimates of $22.72 million, according to data from Fiscal.ai. Meanwhile, the company posted a net loss per share of $1.45, far ahead of Street expectations of $0.58.The company’s subscription revenue for the quarter declined $5.9 million, or 22%, compared to the prior year. This was due to FiscalNote's announced divestitures of Aicel Technologies, Oxford Analytica, Dragonfly Intelligence, and TimeBase, it said.The AI-powered company said that it plans to reduce about 25% of its workforce in the upcoming year to improve its cash position. Meanwhile, for the upcoming quarter, the company forecast revenues of $20 million to $21 million, below Street projections of $23.23 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NOTE">NOTE stock </a>dipped from ‘bearish’ to ‘extremely bearish’ territory over the past 24 hours amid ‘low’ message volumes.One user said that the company would delist and file for bankruptcy soon.<stembedurl>https://stocktwits.com/5DollarNana/message/648080869</stembedurl>&nbsp;Shares of NOTE have fallen more than 51% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

Mark Cuban-Backed NOTE Stock Tumbles 16% Amid Q4 Miss — Analyst Cites Lack Of Catalysts As A Key Concern

Roth Capital lowered the price target on FiscalNote to $3 from $5, and kept a ‘Buy’ rating on the shares after the lackluster Q4 results.

<ul class="summary-bullets"><li>Mobix Labs stated that the goal of the feasibility study is to evaluate technology that is designed to improve the response of munitions and make them more effective as they approach aerial threats such as drones.</li><li>The company added that drones have become a growing challenge in modern warfare, resulting in an increase in demand for technologies to respond with better speed, accuracy, and adaptability.</li><li>Mobix Labs added that the program it has selected for is still in its early stages, stating that it does not involve production or deployment currently.</li></ul>Mobix Labs Inc. (MOBX) on Thursday announced that it has been selected by a major manufacturer to conduct a feasibility study focused on next-generation smart munitions technology for anti-drone applications.“The feasibility program is focused on evaluating technology designed to improve how certain munitions respond as they approach a target,” the company said.Mobix stated that the early-stage program positions it in a segment set for continued investment and innovation.<a href="https://stocktwits.com/symbol/MOBX">Mobix Labs shares</a> were up nearly 27% in Thursday’s opening trade. Retail sentiment on Stocktwits around the company was in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">What Is The Goal Of The Study?</h2>Mobix Labs stated that the goal of the feasibility study is to evaluate technology that is designed to improve the response of munitions and make them more effective as they approach aerial threats such as drones.“Being selected for this feasibility program is an exciting step for Mobix Labs. It reflects both the strength of our technology and the confidence our partners have in our ability to contribute to advanced defense initiatives,” said Mobix Labs CEO Phil Sansone, adding that the goal is to help the munitions respond more intelligently as they approach their targets.The company added that drones have become a growing challenge in modern warfare, resulting in an increase in demand for technologies to respond with better speed, accuracy, and adaptability.<h2 class="st-heading-2">Mobix Says Program Still In Early Stages</h2>Mobix Labs added that the program it has been selected for is still in its early stages, stating that it is currently limited only to feasibility evaluation. The company noted that it does not involve production or deployment at the moment.“If the program advances beyond this stage, Mobix Labs could have the opportunity to participate in additional phases of development,” it added.Mobix Labs provides advanced engineered solutions for aerospace, defense, telecommunications, and other high-reliability markets.<a href="https://stocktwits.com/symbol/MOBX">MOBX stock</a> is up 118% year-to-date, but down 34% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 16% over the past 12 months, while the Vanguard Extended Market Index Fund ETF (VXF) is up 15%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-mulls-transit-fees-strait-of-hormuz-crude-oil-prices-surge/cZ3aLtfRIWw">Iran Reportedly Mulls Transit Fees In Strait Of Hormuz, Targeting A Fifth Of Global Energy Flow As Crude Oil Surges</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Mobix Labs logo is seen displayed on a smartphone screen.

Mobix Labs Tapped For Feasibility Study Of Future Warfare Tech — MOBX Stock Takes Off

The company stated that the early-stage program positions it in a segment set for continued investment and innovation.

<ul><li>Artelo is developing ART27.13, which is a synthetic drug that targets cannabinoid receptors, but only outside the brain.</li><li>The company said preclinical research suggests that peripheral cannabinoid receptor activity may positively influence aqueous humor dynamics and ocular blood outflow.</li><li>Artelo is developing ART27.13 as a once-daily oral drug that could improve body weight, appetite, muscle degeneration, and overall quality of life in cancer patients.</li></ul>&nbsp;Artelo Biosciences Inc. (ARTL) on Wednesday announced that it has secured a fully funded glaucoma study following an agreement with Glaucoma UK and the HSC R&amp;D Division.The study will evaluate the effects of Artelo’s peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences shares</a> were up more than 33% in Wednesday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory with message volumes at ‘high’ levels at the time of writing.—What Is The ART27.13 Treatment?ART27.13 is a synthetic drug that targets cannabinoid receptors, but only outside the brain. The company stated that preclinical research suggests that peripheral cannabinoid receptor activity may positively influence aqueous humor dynamics and ocular blood outflow. These are the two key mechanisms involved in intraocular pressure regulation.“The ophthalmology community has long recognized the potential of cannabinoids in managing intraocular pressure, but their use has been limited by central nervous system effects. ART27.13’s peripherally selective design may overcome this challenge,” said Artelo CEO Greg D. Gorgas.The company is developing ART27.13 as a once-daily, orally administered drug. Artelo says it has the potential to improve body weight, appetite, muscle degeneration, and quality of life in cancer patients.What Does Artelo Do?Artelo is a California-based clinical-stage pharmaceutical company currently developing and commercializing proprietary therapeutics that modulate how fat-based molecules signal between cells.The company has a diversified pipeline of therapeutics for patients with anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 75% year-to-date, but down 61% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 18% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palladyne-ai-subsidiary-wins-us-navy-contract-for-near-hypersonic-missiles/cZ379ezRIgL">Palladyne AI Subsidiary Wins US Navy Contract For Developing New Missiles — PDYN Stock Soars Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is ARTL Stock Soaring Today?

Artelo Biosciences secured a fully-funded study to evaluate the effects of its peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.

<ul class="summary-bullets"><li>The analyst noted that Ocugen has three clinical stage programs in rare and non-rare retinal diseases including OCU400, OCU410ST and OCU410.</li><li>According to data from Koyfin, all six of the six analysts covering OCGN stock rate it ‘Buy’ or higher.</li><li>Earlier this month, Ocugen said that it is targeting making three applications to the U.S. Food and Drug Administration in the next three years.</li></ul>Shares of Ocugen Inc (OCGN) closed up 5% on Tuesday after Canaccord initiated coverage with a ‘Buy’ rating and a whopping price target.Canaccord has a $12 price target on the stock, representing a potential upside of about 415% from the stock’s closing price on Monday.<h2 class="st-heading-2">Canaccord’s Take</h2>The analyst noted that Ocugen has three clinical stage programs in rare and non-rare retinal diseases including OCU400, OCU410ST and OCU410. Canaccord views the data thus far in all three programs as "interesting." It further believes Ocugen's data for OCU410ST in Stargardt disease in the third quarter (Q3) could be a "de-risking event."According to data from Koyfin, all six of the six analysts covering OCGN stock rate it ‘Buy’ or higher. The stock has a 12-month average price target of $10.36, presenting a potential upside of over 300% from current trading levels.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around OCGN stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed optimism for the data from a clinical trial for OCU410 in geographic atrophy (GA) slated for release as early as March.<stembedurl>https://www.stocktwits.com/Kiezan/message/647760765</stembedurl>Another termed buying the stock under $5 as a steal.<stembedurl>https://www.stocktwits.com/jvuskey/message/647759473</stembedurl>Earlier this month, Ocugen said that it is targeting making three applications to the U.S. Food and Drug Administration in the next three years. The company is looking for approval of OCU400 in retinitis pigmentosa, OCU410ST in Stargardt disease and OCU410 in geographic atrophy.The company ended 2025 with cash and restricted vash totalling $18.9 million, and garnered additional proceeds of $22.5 million in a financing round in January 2026, which is expected to allow it to fund its operations into the fourth quarter of 2026.<a href="https://stocktwits.com/symbol/OCGN">OCGN stock</a> has more than quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lantheus-says-fda-pushed-deadline-for-reviewing-tumor-diagnostic-kit-application/cZ3E0YZRIXu">Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data

OCGN Stock - Canaccord has a $12 price target on the stock, representing a potential upside of about 415% from the stock’s closing price on Monday. 

Canaccord has a $12 price target on the stock, representing a potential upside of about 415% from the stock’s closing price on Monday. 

<ul class="summary-bullets"><li>In January, Lunai announced a new product named Sentinel, an AI safeguard that is designed to be embedded directly within large language and scientific foundation models to prevent the generation of novel chemical agents.</li><li>The company said in February that its newly issued patent covers a key first step in its platform that standardizes data and removes bias before AI modeling begins.</li><li>Lunai announced in March that it had furloughed some employees in the U.S. and Canada on February 27, noting that this was a temporary measure.</li></ul>Lunai Bioworks Inc. (LNAI) shares soared more than 200% in Tuesday’s opening trade before shedding some of the gains to hover about 150% higher to chalk a one-month high.While Lunai has&nbsp;not made&nbsp;any&nbsp;announcements recently nor has it made a fresh filing with the U.S. Securities and Exchange Commission (SEC), the stock could be drawing retail interest amid an increased interest in AI on the sidelines of Nvidia’s GTC event.Lunai announced in February that it has locked down its core AI architecture with the issuance of a fresh patent to enable precision disease subtyping.Despite the LNAI stock soaring on Tuesday, the company’s shares are still down more than 93% from the stock’s 52-week high of $7.7.<h2 class="st-heading-2">What Is The Patent About?</h2>Lunai said its patent covers a key first step in its platform that standardizes data and removes bias before AI modeling begins.Since AI drug discovery depends on data quality, the system is designed to detect and fix inconsistencies across genomic, clinical, imaging, and other datasets to improve reliability, the company said.By strengthening this core data layer, Lunai stated that it aims to better identify patient subtypes and link them to the gene networks driving specific diseases.“This patent protects the critical first step in our closed-loop AI architecture, increasing confidence in biomarker discovery, disease stratification, and gene network mapping across our CNS and biodefense programs,” said Lunai CEO David Weinstein.<h2 class="st-heading-2">Lunai Announces Sentinel</h2>In January, Lunai announced a new product named Sentinel, an AI safeguard that is designed to be embedded directly within large language and scientific foundation models to prevent the generation of novel chemical agents.The company said that Sentinel is a real-time biosecurity layer that screens molecular outputs before they are produced, stopping potentially hazardous designs at the source.<h2 class="st-heading-2">Lunai Announces Furloughs</h2>Lunai announced in March that it had furloughed some employees in the U.S. and Canada on February 27, noting that this was a temporary measure.The company also said that its CEO and CFO have agreed to temporarily defer the payment of their salaries during this period. It noted that this measure will be in place until it is able to secure additional capital.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/LNAI">Lunai Bioworks</a> trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.Meanwhile, Koyfin data shows that the short interest in Lunai Bioworks is at 3.3%, up from 1.5% last week.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260317_101902624_png_c94660d562.webp" alt="LNAI stock short interest as on March 17, 2026" width="2400" height="1240"><figcaption>LNAI stock short interest as on March 17, 2026 | Koyfin</figcaption></figure>The company announced in February that it had received a delisting notice from the Nasdaq, while adding that the exchange had granted a request for a hearing, which has been scheduled for March 26, 2026. As a result, the delisting action has been stayed pending a final decision by the exchange.<a href="https://stocktwits.com/symbol/LNAI">LNAI stock</a> is down 42% year-to-date and 93% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF Shares (VTI) and the Vanguard Extended Market Index Fund ETF Shares (VXF) are up 18% in this period.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uber-nvidia-partnership-quells-wall-street-concerns-for-ride-hailing-giant/cZ3EJfXRIX0">Uber's Nvidia Partnership For Autonomous Vehicles Quells Wall Street's Concerns For Ride-Hailing Giant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Lunai Bioworks logo is seen displayed on a smartphone screen

Why Is This Micro-Cap Biotech Stock Up 150% Today?

Despite the LNAI stock soaring on Tuesday, the company’s shares are still down more than 93% from the stock’s 52-week high of $7.7.

Current Price	$206.14
Prev Close	$205.71
Open	$204.16
Dividend Yield	N/A
50-Day Moving Average	$215.06
Beta	N/A
Avg. Volume	497,197.92
PE Ratio	N/A

52-Week High	$223.64
52-Week Low	$146.68
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

VXF
Vanguard Extended Market ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VXF News

VXFVanguard Extended Market ETF